CD274 and urinary bladder cancer: Indeed, a recent study by Powles et al., reports that lack of response to atzeolizumab (anti-PDL1) in bladder cancer patients was associated with an immune-excluded phenotype that corresponded with active TGFβ in peritumoral stroma and a signature of TGFβ signaling [26].